Tumor Immunology and Immunotherapy - Integrated Methods Part B

1st Edition, Volume 636 - March 15, 2020
Editors: Lorenzo Galluzzi, Nils-Petter Rudqvist
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 0 6 6 7 - 6
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 0 6 6 8 - 3

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF˗β) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more.

1. A comprehensive approach to gene expression profiling in immune cells
Sabrina Carpentier, François Romagné and Eric Vivier

2. DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data
Steven F. Gameiro, Farhad Ghasemi, John W. Barrett, James Koropatnick, Anthony C. Nichols, Joe S. Mymryk and Saman Maleki Vareki

3. Using epigenetic data to estimate immune composition in admixed samples
Ankur Chakravarthy and Daniel De Carvalho

4. Metabolomic approaches to study the tumor microenvironment
Giuseppe Astarita, Suraj Dhungana, Bindesh Shrestha and Evagelia C. Laiakis

5. Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives
Florence Marliot, Lucie Lafontaine and Jérôme Galon

6. Transforming growth factor beta (TGF-β) activity in immune-oncology studies
Gabriel Gallo-Oller, Marianna Di Scala, Fernando Aranda and Javier Dotor

7. Isolation of DNA from exosomes
Sheila Spada, Nils Rudqvist and Erik Wennerberg

8. Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses
Shentong Fang, Patrizia Agostinis, Petri Salven and Abhishek D. Garg

9. Computational methods in tumor immunology
Bhavneet Bhinder and Olivier Elemento

10. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq
Christina Plattner, Francesca Finotello and Dietmar Rieder

11. Concurrent in situ analysis of point mutations and immune infiltrate in FFPE cancers
Ann-Marie Baker and Trevor A. Graham

12. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack
Yong-Wei Zhang, Rochelle E. Nasto, Sandra A. Jablonski, Ilya G. Serebriiskii, Rishi Surana, Joseph Murray, Michael Johnson, Rebecca B. Riggins, Robert Clarke, Erica A. Golemis and
Louis M. Weiner

13. An altered miTRAP method for miRNA affinity purification with its pros and cons
Simon Jasinski-Bergner, Christoforos Vaxevanis, Nadine Heimer, Maria-Filothei Lazaridou, Michael Friedrich and Barbara Seliger

14. Identification of immunomodulatory RNA-binding proteins in tumors
Michael Friedrich, Maria-Filothei Lazaridou, Jette Rahn, Christoforos Vaxevanis, Nadine Heimer, Simon Jasinski-Bergner and Barbara Seliger

15. Techniques for the generation of humanized mouse models for immuno-oncology
Chun I. Yu, Florentina Marches, Te-Chia Wu, Jan Martinek and Karolina Palucka

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Nils-Petter Rudqvist

Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.

Affiliations and expertise

Postdoctoral Associate in Radiation Oncology, Weill Cornell Medicine, USA